Analyst Research Report Snapshot


La Jolla Pharmaceutical Company






07 Jul 2015





Companies referenced:

Available for Immediate Download

La Jolla Pharmaceutical (La Jolla) is a development stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for chronic organ failure and cancer. The company focuses on the clinical evaluation of GCS-100, a galectin antagonist for the treatment for chronic organ disease; and LJPC-501, an antagonist of the renin-angiotensin pathway for the treatment for hepatorenal syndrome. In addition, La Jolla is involved in developing new therapies to treat diseases of the liver and lung as well as cancer. The company primarily operates in the US, where it is headquartered in San Diego, California, and employs around seven people. The company did not generate revenues in the fiscal year ended December 2013 and 2012. The company's operating loss was $17.9 million in fiscal 2013, as compared to an operating loss of $10.7 million in 2012. Its net loss was $18.7 million in fiscal 2013, as compared to the net loss of $8.5 million in 2012.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.